Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Bibliographic Details
Main Authors: Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, Gil Harari, David Magalashvili, Polina Sonis, Mark Dolev, Shay Menascu, Shlomo Flechter, Rina Falb, Michael Gurevich
Format: Article
Language:English
Published: SAGE Publishing 2021-05-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/17562864211020082
id doaj-012965fb55bf467c9ed357a5d09cb5f0
record_format Article
spelling doaj-012965fb55bf467c9ed357a5d09cb5f02021-05-29T22:03:27ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28642021-05-011410.1177/17562864211020082Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapiesAnat AchironMathilda MandelSapir Dreyer-AlsterGil HarariDavid MagalashviliPolina SonisMark DolevShay MenascuShlomo FlechterRina FalbMichael Gurevichhttps://doi.org/10.1177/17562864211020082
collection DOAJ
language English
format Article
sources DOAJ
author Anat Achiron
Mathilda Mandel
Sapir Dreyer-Alster
Gil Harari
David Magalashvili
Polina Sonis
Mark Dolev
Shay Menascu
Shlomo Flechter
Rina Falb
Michael Gurevich
spellingShingle Anat Achiron
Mathilda Mandel
Sapir Dreyer-Alster
Gil Harari
David Magalashvili
Polina Sonis
Mark Dolev
Shay Menascu
Shlomo Flechter
Rina Falb
Michael Gurevich
Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
Therapeutic Advances in Neurological Disorders
author_facet Anat Achiron
Mathilda Mandel
Sapir Dreyer-Alster
Gil Harari
David Magalashvili
Polina Sonis
Mark Dolev
Shay Menascu
Shlomo Flechter
Rina Falb
Michael Gurevich
author_sort Anat Achiron
title Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
title_short Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
title_full Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
title_fullStr Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
title_full_unstemmed Author response to: Correspondence to humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
title_sort author response to: correspondence to humoral immune response to covid-19 mrna vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
publisher SAGE Publishing
series Therapeutic Advances in Neurological Disorders
issn 1756-2864
publishDate 2021-05-01
url https://doi.org/10.1177/17562864211020082
work_keys_str_mv AT anatachiron authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies
AT mathildamandel authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies
AT sapirdreyeralster authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies
AT gilharari authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies
AT davidmagalashvili authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies
AT polinasonis authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies
AT markdolev authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies
AT shaymenascu authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies
AT shlomoflechter authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies
AT rinafalb authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies
AT michaelgurevich authorresponsetocorrespondencetohumoralimmuneresponsetocovid19mrnavaccineinpatientswithmultiplesclerosistreatedwithhighefficacydiseasemodifyingtherapies
_version_ 1721421155998367744

Similar Items